How big is Arcadia Biosciences, Inc.?

As of Jun 18, Arcadia Biosciences, Inc. has a market capitalization of 6.81 million, with net sales of 5.27 million and a net profit of -0.77 million over the latest four quarters. The company reported shareholder's funds of 6.22 million and total assets of 13.52 million as of Dec 24.

Market Cap: As of Jun 18, Arcadia Biosciences, Inc. has a market capitalization of 6.81 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Arcadia Biosciences, Inc. reported net sales of 5.27 million and a net profit of -0.77 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.22 million and total assets of 13.52 million.

What does Arcadia Biosciences, Inc. do?

Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing traits for crops, with a market capitalization of $6.81 million. As of March 2025, it reported net sales of $1 million and a net profit of $3 million.

Overview: <BR>Arcadia Biosciences, Inc. is an agricultural biotechnology trait company operating in the Chemicals & Petrochemicals industry, with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6.81 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 7.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.35 <BR>Return on Equity: 4.88% <BR>Price to Book: 0.76<BR><BR>Contact Details: <BR>Address: 202 Cousteau Pl Ste 200, DAVIS CA : 95618-7761 <BR>Tel: 1 530 7567077 <BR>Fax: 1 530 7567027 <BR>Website: https://arcadiabio.com/

Should I buy, sell or hold Arcadia Biosciences, Inc.?

Who are in the management team of Arcadia Biosciences, Inc.?

As of March 2022, the management team of Arcadia Biosciences, Inc. includes Chairman Kevin Comcowich, CEO Matthew Plavan, and Directors Jamie Bechtel, Dr. Albert Bolles, Peter Gajdos, Lilian Shackleford Murray, and Gregory Waller. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Arcadia Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Kevin Comcowich, Chairman of the Board<BR>- Mr. Matthew Plavan, Chief Executive Officer and Director<BR>- Jamie Bechtel, Director<BR>- Dr. Albert Bolles, Director<BR>- Peter Gajdos, Director<BR>- Ms. Lilian Shackleford Murray, Director<BR>- Mr. Gregory Waller, Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Arcadia Biosciences, Inc. overvalued or undervalued?

As of March 30, 2022, Arcadia Biosciences, Inc. is considered a risky investment due to its low P/E and PEG ratios, negative EV to EBITDA, and underperformance compared to the S&P 500, indicating it may be overvalued.

As of 30 March 2022, the valuation grade for Arcadia Biosciences, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its P/E ratio of 7, which is significantly lower than the industry average, and a PEG ratio of 0.07, suggesting limited growth prospects. Additionally, the EV to EBITDA ratio of -0.76 further highlights the company's financial struggles.<BR><BR>In comparison to peers, Arcadia's valuation metrics are concerning; for instance, Oil-Dri Corp. of America has a P/E ratio of 25.16, showcasing a stark contrast in valuation. Other risky peers, such as LSB Industries, Inc. and Bioceres Crop Solutions Corp., also reflect negative EV to EBITDA ratios, indicating that Arcadia is not alone in its challenges but still stands out with its particularly low ratios. Over the past year, while Arcadia's stock returned 26.38%, it underperformed against the S&P 500's 17.14%, reinforcing the notion that the stock may be overvalued in the current market context.

Is Arcadia Biosciences, Inc. technically bullish or bearish?

As of September 10, 2025, Arcadia Biosciences, Inc. has shifted to a mildly bearish trend, indicated by bearish MACD and moving averages, underperforming the S&P 500 with a return of -18.01% over the last month and -38.09% year-to-date.

As of 10 September 2025, the technical trend for Arcadia Biosciences, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and mildly bearish signals from the Bollinger Bands and KST on the weekly. The Dow Theory indicates no trend on the weekly but is mildly bearish on the monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the last month with a return of -18.01% compared to the S&P 500's 2.33%, and it has significantly lagged over the year-to-date with a return of -38.09% versus the S&P 500's 12.22%.